“But we must move far more quickly than we did with oral PrEP if we are to have a real impact on the epidemic. This new coalition being formed will prioritise the acceleration of affordable, equitable and widespread access to injectable, long-acting cabotegravir for PrEP without delay.
“However, we recognise this is just the first step on this path for long-acting cabotegravir for PrEP. Speedy technology transfer and low-cost pricing have still not been secured. Until then, the promise of accessible, affordable CAB-LA will not be realised. Afrocab and our community partners will continue to advocate around these issues until they are resolved.”for the use of CAB-LA on Thursday.
The women, based in Botswana, Eswatini, Kenya, Malawi, South Africa, Uganda and Zimbabwe, had initially been part of a clinical trial to compare oral and injectable PrEP .
Sounds like an undercover vaccine